Filing Analysis
Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders on December 1, 2025. All proposals, including the election of directors and ratification of auditors, were approved by stockholders.
📋 Key Facts
- The 2025 Annual Meeting was held virtually on December 1, 2025.
- Quorum reached: 22,327,761 shares (85.06% of issued and outstanding shares).
- Dr. Jerel Banks and Megan Boston were elected to the Board of Directors.
- The appointment of the Independent Registered Public Accounting Firm was ratified.
- Advisory vote on executive compensation was approved.
Benitec Biopharma Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025, and provided an operational update via a press release.
📋 Key Facts
- Report date: November 14, 2025
- Reporting period: Fiscal quarter ended September 30, 2025
- The filing includes an operational update alongside financial results
- Information is furnished under Item 2.02 and not 'filed' for liability purposes under Section 18 of the Exchange Act
Benitec Biopharma Inc. announced two concurrent offerings—an underwritten public offering and a registered direct offering—aiming to raise approximately $100 million in gross proceeds at $13.50 per share.
🚩 Red Flags
- Significant dilution: The issuance of over 7.4 million new shares represents substantial equity dilution for existing shareholders.
- Related-party connection: Kishen Mehta, a Portfolio Manager at Suvretta Capital (which is subject to the lock-up), serves on the company's board of directors.
📋 Key Facts
- Underwritten Offering: 5,930,000 shares of common stock at $13.50 per share, plus a 30-day option for underwriters to purchase up to 889,500 additional shares.
- Direct Offering: 1,481,481 shares sold to Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. at $13.50 per share.
- Total expected gross proceeds: approximately $100 million before fees and expenses.
- Underwriters include Leerink Partners LLC, TD Securities (USA) LLC, and Evercore Group L.L.C.
- Lock-up agreement: Insiders including Suvretta Capital Management, LLC are subject to a 90-day lock-up period.
- Expected closing date: November 7, 2025.
Benitec Biopharma announced the appointment of Dr. Sharon Mates to its Board of Directors and reported that the FDA has granted Fast Track Designation for its lead candidate, BB-301.
📋 Key Facts
- Dr. Sharon Mates appointed as a Class I director effective November 3, 2025.
- FDA granted Fast Track Designation to BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
- Dr. Mates to receive stock options with an aggregate value of $450,000 based on the Nov 5, 2025 closing price.
- Options vest in full at the earlier of the 2026 annual meeting or the first anniversary of the grant date.
Benitec Biopharma Inc. filed an 8-K to furnish its full year financial results for the period ended June 30, 2025, and provided an operational update via a press release.
📋 Key Facts
- The filing reports financial results for the full fiscal year ended June 30, 2025.
- The company issued an operational update alongside the financial results.
- Information was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition).
Benitec Biopharma Inc. has determined that its previously issued financial statements for the quarters ended December 31, 2024, and March 31, 2025, should no longer be relied upon due to errors in recording non-cash share-based compensation expenses.
🚩 Red Flags
- Non-reliance on previously issued financial statements (Item 4.02)
- Material errors in accounting for share-based compensation
- Systemic failure during data migration leading to multi-quarter misstatements
📋 Key Facts
- The error originated from a November 2023 migration of equity awards data to a new information system that was incorrectly configured.
- The misconfiguration resulted in the understatement of share-based compensation expense, additional paid-in capital, accumulated deficit, net loss, and loss per share.
- The impact was immaterial prior to Q4 2024 but became material for the periods ended Dec 31, 2024, and March 31, 2025.
- Restatements will be included in the upcoming 2025 Form 10-K.
- The company's independent auditor is Baker Tilly US, LLP.
Benitec Biopharma Inc. announced the successful completion of dosing for the final subject in Cohort 1 of its Phase 1b/2a clinical study for BB-301. The Data Safety Monitoring Board has recommended continuing enrollment, with Cohort 2 expected to begin in Q4 2025.
📋 Key Facts
- The sixth and final subject in Cohort 1 was safely treated with a Low Dose of BB-301 on July 9, 2025.
- Data Safety Monitoring Board (DSMB) recommended the continuation of enrollment for the Phase 1b/2a Clinical Treatment Study (NCT06185673).
- Enrollment for Cohort 2 is projected to commence in the fourth calendar quarter of 2025.
Benitec Biopharma Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Reporting period: Fiscal quarter ended March 31, 2025.
- Filing date: May 14, 2025.
Benitec Biopharma Inc. completed two simultaneous offerings on March 26, 2025: an underwritten offering and a registered direct offering. The company raised capital through the sale of common stock and pre-funded warrants to various investors.
🚩 Red Flags
- Significant dilution potential due to a large number of outstanding common warrants (5.8M) and pre-funded warrants (15.2M), which together represent over 79% of the current shares outstanding.
📋 Key Facts
- Underwritten Offering: Sale of 1,143,000 shares of Common Stock at $13.00 per share.
- Pre-funded Warrants (Underwritten): 300,000 warrants to purchase common stock at an exercise price of $0.0001 for $12.999 per warrant.
- Direct Offering: Sale of 900,000 shares of Common Stock to Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. at $13.00 per share.
- Post-closing capital structure (as of March 26, 2025): 25,546,288 shares outstanding; 5,876,866 common warrants outstanding; and 15,270,807 pre-funded warrants outstanding.
- Total new shares/warrants issued via these offerings: 2,043,000 shares and 300,000 pre-funded warrants.
Benitec Biopharma Inc. entered into a Registration Rights Agreement with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. following a registered direct offering. The agreement requires the company to register the shares sold in the offering for resale within 60 days.
🚩 Red Flags
- Potential future dilution as the company is obligated to register shares sold in a direct offering for resale by institutional purchasers.
📋 Key Facts
- Entered into a Registration Rights Agreement on March 26, 2025.
- Counterparties are Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd.
- The agreement is linked to a previously announced registered direct offering via Form S-3 (File No. 333-282957).
- Company must file a registration statement for the resale of shares within 60 days of the Direct Offering closing.
Benitec Biopharma Inc. announced two concurrent offerings—an underwritten offering and a registered direct offering—aiming to raise approximately $30 million in gross proceeds at $13.00 per share. The funds are intended for product development, working capital, and general corporate purposes.
🚩 Red Flags
- Related-party transaction: The Direct Offering is being conducted with Averill Master Fund, which are affiliates of Suvretta Capital (a major shareholder holding ~38% prior to the offering).
- Potential dilution: Issuance of 1.14M shares plus 300k warrants and 900k direct shares represents significant new equity issuance.
📋 Key Facts
- Underwritten Offering: 1,143,000 shares of common stock and 300,000 pre-funded warrants at $13.00 per share (warrants at $12.9999).
- Direct Offering: 900,000 shares of common stock to Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. at $13.00 per share.
- Total expected gross proceeds: approximately $30 million before expenses.
- Underwriters include Leerink Partners LLC and TD Securities (USA) LLC; Citizens Capital Markets acted as lead manager.
- The offerings are being conducted via a previously effective Form S-3 registration statement.
- A 90-day lock-up agreement has been established for the Company, executive officers, directors, and Suvretta Capital Management, LLC.
Benitec Biopharma announced positive interim clinical results from its Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD). The data showed significant improvements in swallowing function and reductions in symptom burden across three treated subjects with no severe adverse events reported.
🚩 Red Flags
- The company's forward-looking statements include a standard warning regarding the ability 'to continue as a going concern,' though this is boilerplate language and not an explicit going concern disclosure in the current filing.
📋 Key Facts
- Interim results from Phase 1b/2a single-arm, open-label study of BB-301 for OPMD presented on March 19, 2025.
- Three subjects were treated with a low dose of BB-301 (1.2e13 vg/Subject) and showed clinically meaningful improvements in swallowing function.
- Subject 1 (Inefficient Swallowing): Achieved a 41% reduction in total dysphagic symptom burden (SSQ Total Score) at 12 months post-treatment.
- Subject 2 (Ineffective Swallowing): Achieved a 91% reduction in SSQ Total Score at 12 months, reaching a clinically normal swallowing profile (68 units).
- Subject 3 (Ineffective Swallowing): Achieved a 68% reduction in SSQ Total Score at 3 months, also reaching a clinically normal swallowing profile (70 units).
- No Severe Adverse Events (SAEs) were observed in the treated subjects.
- Enrollment is ongoing; the sixth and final subject of Cohort 1 is expected to be treated in 2Q 2025.
Benitec Biopharma Inc. issued an 8-K to announce the presentation of interim clinical trial data from its BB-301 Phase 1b/2a study at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference.
📋 Key Facts
- Company announced interim clinical trial data for BB-301 (Phase 1b/2a study).
- Data presentation occurred at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas.
- The filing was made on March 19, 2025.
Benitec Biopharma Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2024, and provided an operational update via a press release.
📋 Key Facts
- Reporting period: Fiscal quarter ended December 31, 2024
- Filing date: February 14, 2025
- The filing includes results of operations and financial condition under Item 2.02.
- An operational update was included in the accompanying press release (Exhibit 99.1).
This 8-K/A is an amendment to a previous filing, specifically supplementing the disclosure regarding the appointment of Sophie Mukadam as Chief Operating Officer. It details the compensatory arrangement involving a grant of stock options.
📋 Key Facts
- Sophie Mukadam appointed as Chief Operating Officer effective January 1, 2025.
- Grant of 300,000 nonqualified stock options approved on December 27, 2024.
- Exercise price set at $12.00 per share (matching the closing price on the grant date).
- Vesting schedule: Sixteen equal quarterly installments starting March 31, 2025, contingent on continued service.
- Acceleration clause: Unvested options become fully vested upon a Change in Control.
Benitec Biopharma announced several executive leadership changes and compensation adjustments effective January 1, 2025. This includes the appointment of a new COO and the promotion of the current Executive Director to CFO.
🚩 Red Flags
- Significant increase in executive compensation (salaries and bonuses) for the CEO and CFO.
📋 Key Facts
- Sophie Mukadam appointed as Chief Operating Officer (COO), effective Jan 1, 2025; base salary $500,000 with 40% target bonus.
- Megan Boston confirmed as Secretary and promoted to Chief Financial Officer (CFO), effective Jan 1, 2025.
- CEO Dr. Jerel Banks granted 2,310,000 nonqualified stock options at an exercise price of $12.18 per share.
- CFO Megan Boston granted 720,000 nonqualified stock options at an exercise price of $12.18 per share.
- CEO base salary increased to $667,000 with a 55% target bonus effective Jan 1, 2025.
- CFO base salary increased to $415,000 with a 40% target bonus effective Jan 1, 2025.
Benitec Biopharma Inc. announced that stockholders approved an amendment to its Certificate of Incorporation during the 2024 Annual Meeting held on December 4, 2024. The amendment authorizes the issuance of up to 5,000,000 shares of preferred stock.
🚩 Red Flags
- Authorization of significant new equity (5 million preferred shares) often precedes dilutive financing rounds or convertible debt issuances common in micro-cap biotech companies.
📋 Key Facts
- Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation at the 2024 Annual Meeting on December 4, 2024.
- The amendment authorizes the issuance of up to 5,000,000 shares of preferred stock (par value $0.0001).
- The Amendment became effective with the Secretary of State of Delaware on December 9, 2024.
- The authorization includes a corresponding change to the number of authorized shares of capital stock.
Benitec Biopharma Inc. reported the results of its 2024 Annual Meeting of Stockholders held on December 4, 2024. All proposed items, including director elections and an amendment to authorize preferred stock, were approved by stockholders.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The 2024 Annual Meeting was held virtually on December 4, 2024.
- Quorum reached: 17,993,811 shares (90.81% of issued and outstanding shares).
- Proposal 1: Election of J. Kevin Buchi and Peter Francis to the Board was approved.
- Proposal 2: Ratification of the Independent Registered Public Accounting Firm was approved with 17,978,704 votes 'For'.
- Proposal 3: Advisory vote on Executive Compensation (Say-on-Pay) was approved.
- Proposal 4: Amendment to Certificate of Incorporation to authorize up to 5,000,000 shares of Preferred Stock was approved.
Benitec Biopharma Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Fiscal quarter ended September 30, 2024.
- Filing date: November 14, 2024.
Benitec Biopharma Inc. announced the approval of discretionary bonus payments for its Executive Chairman/CEO and Executive Director based on performance for fiscal year 2024.
🚩 Red Flags
- Discretionary bonuses paid to top executives (CEO and Executive Director) in a micro-cap setting can sometimes be viewed as a way to extract cash, though the filing does not indicate financial distress.
📋 Key Facts
- Dr. Jerel Banks (Executive Chairman and CEO) approved for a $360,360 discretionary bonus.
- Megan Boston (Executive Director) approved for a $161,580 discretionary bonus.
- Bonuses relate to performance during the fiscal year ending June 30, 2024.
- Ms. Boston's bonus was converted from AUD to USD at a rate of 0.67.
Benitec Biopharma Inc. issued a press release regarding interim clinical trial data from its BB-301 Phase 1b/2a study. The data covers the first two subjects treated with a Low Dose of BB-301 at specific timepoints.
📋 Key Facts
- Interim clinical trial data released for BB-301 Phase 1b/2a study.
- Data pertains to the first two subjects treated with the 'Low Dose' of BB-301.
- Subject 1 data is at the 270-day timepoint; Subject 2 data is at the 180-day timepoint.
- The disclosure was made via Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for liability purposes under Section 18.
Benitec Biopharma Inc. entered into an 'at-the-market' (ATM) sales agreement with Leerink Partners LLC to facilitate the potential sale of up to $75 million in common stock.
🚩 Red Flags
- Potential significant dilution to existing shareholders due to the $75M ATM offering capacity.
- The use of proceeds for 'working capital' often indicates a need for immediate liquidity in micro-cap biotech firms.
📋 Key Facts
- Entered into a Sales Agreement with Leerink Partners LLC on October 11, 2024.
- Aggregate offering amount is up to $75 million in common stock.
- The offering will be conducted as an 'at-the-market' (ATM) offering under Rule 415.
- Agent (Leerink Partners LLC) receives a 3.0% commission on gross proceeds.
- Proceeds are intended for product candidate development, working capital, and general corporate purposes.
Benitec Biopharma Inc. announced the exercise of various warrants by Suvretta Capital Management, LLC and other holders, resulting in the issuance of over 7 million shares for approximately $21.1 million in proceeds. This follows a prior stockholder approval to waive beneficial ownership limitations.
🚩 Red Flags
- Significant dilution: The issuance of 7.1M shares represents a substantial portion (approx. 40%) of the company's current 17.8M outstanding shares.
- Concentration of ownership: Suvretta Capital has negotiated significant ownership thresholds, increasing potential for concentrated control/influence.
📋 Key Facts
- Suvretta Funds exercised three tranches of warrants: 588,236 Series 2 warrants ($1.9299/share), 5,181,347 warrants ($3.86/share), and 1,368,180 pre-funded warrants ($0.0001/share).
- Total shares issued to Suvretta Funds: 7,137,763 common shares.
- Aggregate proceeds from these exercises: approximately $21,135,373.
- Suvretta Capital agreed to a new beneficial ownership cap of 49.9% following the waiver of the previous 19.99% limitation.
- As of October 8, 2024, total outstanding common stock is 17,893,765 shares.
Benitec Biopharma Inc. filed an 8-K to furnish its full year financial results for the period ended June 30, 2024, and provided an operational update via a press release.
📋 Key Facts
- Report date: September 26, 2024
- Reporting period: Full year ended June 30, 2024
- The filing includes results of operations and financial condition updates
- An operational update was provided alongside the financial results
Benitec Biopharma Inc. held a Special Meeting of Stockholders on August 29, 2024, where shareholders approved two key proposals: a Nasdaq listing requirement proposal and an amendment to the company's 2020 Equity and Incentive Compensation Plan.
🚩 Red Flags
- The necessity of a Nasdaq-related proposal (Proposal 1) often implies the company is working to maintain compliance with exchange listing requirements, which can be a precursor to delisting risks if not resolved.
📋 Key Facts
- Special Meeting held on August 29, 2024, with 58.97% of issued and outstanding shares represented (5,947,860 shares).
- Proposal 1 (Nasdaq Proposal) was approved by a significant majority: 5,868,978 votes 'For' vs. 13,614 'Against'.
- Proposal 2 (Amendment to 2020 Equity and Incentive Compensation Plan) was approved with 5,024,173 votes 'For' vs. 232,406 'Against'.
- The Adjournment Proposal was not required as sufficient votes were present for the primary proposals.
Benitec Biopharma Inc. issued a press release regarding interim clinical trial data from its BB-301 Phase 1b/2a study. The data pertains to the first subject treated with a Low Dose of BB-301 at the 180-day timepoint.
📋 Key Facts
- Release of interim clinical trial data for BB-301 Phase 1b/2a study.
- Data focuses on the first subject treated with a 'Low Dose' of BB-301.
- The reported milestone is at the 180-day timepoint.
Benitec Biopharma Inc. announced the appointment of Kishan (Kishen) Mehta to its Board of Directors, effective June 26, 2024. This appointment is pursuant to a previously disclosed Board Designation Agreement with Suvretta Capital Management, LLC.
🚩 Red Flags
- Appointment is driven by a Board Designation Agreement with an institutional investor (Suvretta Capital Management), which can sometimes indicate activist involvement or pressure from major shareholders.
📋 Key Facts
- Kishan Mehta appointed as Class I director effective June 26, 2024.
- Mehta will serve until the Company's 2026 annual meeting of stockholders.
- Appointment is part of a Board Designation Agreement with Suvretta Capital Management, LLC (disclosed April 19, 2024).
- Mehta appointed to the Nominating and Corporate Governance Committee.
- Board has determined Mehta is independent per Nasdaq rules.
Benitec Biopharma Inc. filed an 8-K to furnish its quarterly press release regarding financial results for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard disclosure of quarterly earnings via Exhibit 99.1.
- Reporting period: Fiscal quarter ended March 31, 2024.
- Filing date: May 13, 2024.
Benitec Biopharma Inc. entered into a securities purchase agreement for a private placement of approximately $40 million in common stock and pre-funded warrants. The offering includes significant participation from institutional investors and involves board designation rights for one investor.
🚩 Red Flags
- Significant dilution: The issuance of over 5.7 million common shares and 2.5 million warrant shares represents substantial potential dilution for existing shareholders.
- Board Designation Side Agreement: Suvretta Capital Management, LLC is entitled to appoint Kishen Mehta to the Board of Directors as part of the deal.
📋 Key Facts
- Private placement of 5,749,152 shares of common stock at $4.80 per share.
- Issuance of pre-funded warrants to purchase up to 2,584,239 shares at an exercise price of $0.0001 per share.
- Expected aggregate gross proceeds: approximately $40.0 million (before expenses).
- Participating investors include Suvretta Capital Management, LLC, Adage Capital Partners, L.P., and Franklin Resources Inc.
- Closing date expected on April 22, 2024.
- The company will enter into a Registration Rights Agreement to register the shares for resale within 30-60 days of closing.
Benitec Biopharma Inc. issued an 8-K to announce the release of interim clinical trial data from its BB-301 Phase 1b/2a study. The company presented this data during a live virtual R&D event on April 18, 2024.
📋 Key Facts
- Announced interim clinical trial data for the BB-301 Phase 1b/2a study.
- Data was presented at a live virtual R&D event held on April 18, 2024.
- The filing includes Exhibit 99.1 (Press Release) and Exhibit 99.2 (Presentation).
Benitec Biopharma Inc. announced the approval of nonqualified stock option grants to its CEO, Dr. Jerel Banks, and Executive Director, Megan Boston.
🚩 Red Flags
- None identified; these are standard equity incentive grants for retention and alignment.
📋 Key Facts
- Dr. Jerel Banks (CEO) granted 466,554 nonqualified stock options.
- Megan Boston (Executive Director) granted 200,004 nonqualified stock options.
- Exercise price for both grants is $5.21 per share, matching the March 6, 2024 closing price.
- Options vest in three equal annual installments over three years.
- Accelerated vesting occurs upon a Change in Control.
Benitec Biopharma Inc. filed an 8-K to announce its financial results for the fiscal quarter ended December 31, 2023. The filing serves as a formal announcement of the earnings release issued on February 13, 2024.
📋 Key Facts
- The company reported financial results for the fiscal quarter ended December 31, 2023.
- The report was filed on February 13, 2024.
- Results are provided via a press release attached as Exhibit 99.1.